Disease/Infection News

RSS

Major international health conference to be held next week in Singapore

The world is rapidly shrinking at the same time that medical collaborations are expanding - for the benefit of patient care right across the globe, a major international health conference in Singapore will hear next week.

4 Nov 2014

Precision awarded $28 million contract to provide management of disease-study specimens for NIAID

Precision for Medicine announced today that its subsidiary, Precision Bioservices, Inc., has been awarded a 7-year contract of up to $28 million to provide management and oversight of disease-study specimens for the National Institute of Allergy and Infectious Diseases.

4 Nov 2014

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Ruthigen, Inc., announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

Scientists obtain first structure of the immature form of HIV

Scientists at the European Molecular Biology Laboratory in Heidelberg, Germany and collaborators from Heidelberg University, in the joint Molecular Medicine Partnership Unit, have obtained the first structure of the immature form of HIV at a high enough resolution to pinpoint exactly where each building block sits in the virus.

4 Nov 2014

Nasal vaccine shows promise against Ebola virus

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.

4 Nov 2014

New research sheds light on future efforts to eradicate HIV from the body in human patients

Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the virus targets, called CD4 or helper T cells, but other infected cells as well.

3 Nov 2014

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information.

3 Nov 2014

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas announced today that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis.

3 Nov 2014

WHO conducts formal review of PPE guidelines for healthcare workers in response to Ebola outbreak

As part of WHO's commitment to safety and protection of healthcare workers and patients from transmission of Ebola virus disease, WHO has conducted a formal review of personal protective equipment (PPE) guidelines for healthcare workers and is updating its guidelines in context of the current outbreak.

3 Nov 2014

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

In support of a bold quest to rid the world entirely of malaria, the Bill & Melinda Gates Foundation today announced an award of US$156 million to PATH to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure that parasite reintroduction is prevented by providing what could be called an "immunological bed net."

3 Nov 2014

New, easy-to-use test to accelerate progress toward eliminating onchocerciasis in Africa

A new test will accelerate global progress toward eliminating onchocerciasis, a leading cause of preventable blindness in Africa. PATH, an international nonprofit health organization, today announced the availability of the SD BIOLINE Onchocerciasis IgG4 rapid test, manufactured and distributed by Standard Diagnostics, Inc.

3 Nov 2014

Researchers develop mouse model to improve basic research on Ebola treatments, vaccines

Researchers at the University of North Carolina at Chapel Hill and colleagues have developed the first genetic strain of mice that can be infected with Ebola and display symptoms similar to those that humans experience.

31 Oct 2014

University of Adelaide-led project develops new test to eradicate H5N1 bird flu

A University of Adelaide-led project has developed a new test that can distinguish between birds that have been vaccinated against the H5N1 strain of avian influenza virus or "bird flu" with those that have been naturally infected.

31 Oct 2014

Profectus BioSciences gets funding to develop VesiculoVax Zaire-Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.

31 Oct 2014

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

31 Oct 2014

Google search data can provide more accurate real time picture of flu

Researchers have found that Google search data really can provide a more accurate real time picture of current flu infections.

31 Oct 2014

Specific complex carbohydrates in human milk protect against Norovirus

Norovirus is the most common cause of viral epidemic gastroenteritis. About 18% of all gastroenteritis infections are caused by Norovirus affecting 267 million people worldwide every year. According to information of the Robert Koch-Institute more than 200.000 Norovirus-infections were registered in Germany during 2012 and 2013. The Centers for Disease Control and Prevention report up to 21 million Norovirus-infections per year in the USA.

30 Oct 2014

Research shows that copper could help to prevent Ebola spread

Research from the University of Southampton has indicated that copper could help to prevent the spread of Ebola.

30 Oct 2014

Illicit drug use, tourism contribute to elevated HIV/AIDS risk in the Dominican Republic

The Caribbean has the second highest global human immunodeficiency virus (HIV) prevalence in the world outside of Sub-Saharan Africa, with HIV/AIDS as leading cause of death among people aged 20–59 years within the region. Particularly hard-hit are the Dominican Republic (DR) and Haiti, on the island of Hispaniola, accounting for approximately 70% of all people living with HIV in the Caribbean region.

30 Oct 2014

Disease/Infection News

Major international health conference to be held next week in Singapore

Precision awarded $28 million contract to provide management of disease-study specimens for NIAID

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Scientists obtain first structure of the immature form of HIV

Nasal vaccine shows promise against Ebola virus

New research sheds light on future efforts to eradicate HIV from the body in human patients

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

WHO conducts formal review of PPE guidelines for healthcare workers in response to Ebola outbreak

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

New, easy-to-use test to accelerate progress toward eliminating onchocerciasis in Africa

Researchers develop mouse model to improve basic research on Ebola treatments, vaccines

University of Adelaide-led project develops new test to eradicate H5N1 bird flu

Profectus BioSciences gets funding to develop VesiculoVax Zaire-Ebola virus vaccine

Dosing of antiretroviral medication to prevent HIV infection differs by sex

Google search data can provide more accurate real time picture of flu

Specific complex carbohydrates in human milk protect against Norovirus

Research shows that copper could help to prevent Ebola spread

Illicit drug use, tourism contribute to elevated HIV/AIDS risk in the Dominican Republic

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News